Clinical trial NCT03485677: Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
Official title: Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Gaucher's Disease Type I
Gaucher's Disease Type III
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2018-04-02
Enrollment: 57
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: Primary Objective:

Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (≥2 to \<18 years old).

Secondary Objective:

Evaluate the efficacy of eliglustat and quality of life in pediatric patients (≥2 to \<18 years old).

Detailed description: The study will include a screening period of up to 60 days (Day -60 to -1), a primary analysis treatment period (Day 1 to Week 52), a long-term treatment period (Week 53 to Week 104), and an extension period continuing up to Week 364 (for patients who continue to demonstrate the clinical benefit from eliglustat monotherapy at Week 104). After study completion, patients will be encouraged to enroll in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Eligibility criteria: Inclusion criteria :

* The patient is 2 to \<18 years old at the time of informed consent.
* Male and female patients with a clinical diagnosis of Gaucher disease (GD) type 1 or type 3 with documented deficiency of acid beta-glucosidase activity by enzyme assay and glucocerebrosidase (GBA) genotype.
* Postmenarchal female patients must have a documented negative pregnancy test prior to enrollment and throughout the study. Patients must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use a medically accepted form of contraception throughout the study.

Cohort 1 (Eliglustat monotherapy):

* Patients must have been receiving an enzyme replacement therapy (ERT) for a minimum of 24 months at a monthly dose equivalent to 30 U/kg to 130 U/kg of Cerezyme® (imiglucerase) with treatment ongoing at the time of enrollment. Patients must be at pre-specified treatment goals, as defined by:

  * Hemoglobin level for ages 2 to \<12 years: ≥11.0 g/dL; for ages 12 to \<18 years: ≥11.0 g/dL for females and ≥12.0 g/dL for males;
  * Platelet count ≥100,000/mm3;
  * Spleen volume \<10.0 multiples of normal (MN);
  * Liver volume \<1.5 MN;
  * Absence of GD related pulmonary disease, and severe bone disease, as defined below for Cohort 2.

Cohort 2 (Eliglustat plus imiglucerase):

* Patients must have been receiving an ERT for a minimum of 36 months at a dose equivalent to at least 60 U/kg of imiglucerase every 2 weeks, or at the maximum dose locally approved, at the time of enrollment with treatment ongoing at the time of enrollment and the dose stable for at least the 6 months preceding enrollment. Patients must have severe clinical manifestations of GD, as defined by the presence of at least one of the following:

  * GD related pulmonary disease such as interstitial lung disease (ILD). The diagnosis of ILD must be confirmed by the presence of reticulonodular densities on chest X-ray; AND/OR
  * Symptomatic bone disease characterized by pathological fracture, osteonecrosis, osteopenia/osteoporosis, or bone crisis occurring in the 12 months prior to enrollment; AND/OR
  * Persistent thrombocytopenia (\<80,000/mm3) related to GD.

Exclusion criteria:

* Substrate reduction therapy for GD within 6 months prior to enrollment.
* Partial or total splenectomy if performed within 2 years prior to enrollment
* The patient is transfusion dependent, a history of esophageal varices or liver infarction, elevated liver enzymes, significant congenital cardiac defect, coronary artery disease or left sided heart failure; clinically significant arrhythmias or conduction defect such as Type 2 second degree or third degree atrioventricular (AV) block, complete bundle branch block, prolonged QTc interval, or sustained ventricular tachycardia (VT).
* The patient has any clinically significant disease other than GD.
* The patient has neurological symptoms other than oculomotor apraxia at study entry.
* The patient has received an investigational product within 30 days prior to enrollment.
* The patient is unable to receive treatment with imiglucerase due to a known hypersensitivity or is unwilling to receive imiglucerase treatment every 2 weeks.
* The patient has a known hereditary galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption, or is a CYP2D6 ultra-rapid metabolizer or indeterminate metabolizer.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Assessment of pharmacokinetic (PK) parameter of eliglustat: Cmax
timeFrame: Weeks 2, 13, 26 and 52
measure: Assessment of PK parameter of eliglustat: AUC
timeFrame: Weeks 2 and 52
measure: Adverse Events
timeFrame: Up to Week 364
Secondary outcomes:
measure: Change in hemoglobin level
timeFrame: Baseline and Week 52
measure: Change in platelet count
timeFrame: Baseline and Week 52
measure: Change in liver volume
timeFrame: Baseline and Week 52
measure: Change in spleen volume
timeFrame: Baseline and Week 52
measure: Pulmonary disease improvement
timeFrame: Baseline and Week 52
measure: Bone disease improvement
timeFrame: Baseline and Week 52
measure: Thrombocytopenia
timeFrame: Baseline and Week 52
measure: Quality of Life
timeFrame: Baseline and Week 52
Other outcomes:
Locations:
city: Capital Federal
country: Argentina
facility: Investigational Site Number : 0320001
state: Buenos Aires
city: Calgary
country: Canada
facility: Investigational Site Number : 1240002
state: Alberta
city: Vancouver
country: Canada
facility: Investigational Site Number : 1240003
state: British Columbia
city: Toronto
country: Canada
facility: Investigational Site Number : 1240001
state: Ontario
city: BRON Cedex
country: France
facility: Investigational Site Number : 2500002
city: Roma
country: Italy
facility: Investigational Site Number : 3800002
city: Koshigaya-shi
country: Japan
facility: Investigational Site Number : 3920002
state: Saitama
city: Minato-ku
country: Japan
facility: Investigational Site Number : 3920001
state: Tokyo
city: Moscow
country: Russian Federation
facility: Investigational Site Number : 6430001
city: Moscow
country: Russian Federation
facility: Investigational Site Number : 6430004
city: St-Petersburg
country: Russian Federation
facility: Investigational Site Number : 6430005
city: Tomsk
country: Russian Federation
facility: Investigational Site Number : 6430002
city: Barakaldo
country: Spain
facility: Investigational Site Number : 7240002
state: Bizkaia
city: Esplugues de Llobregat
country: Spain
facility: Investigational Site Number : 7240001
state: Catalunya [Cataluña]
city: Zaragoza
country: Spain
facility: Investigational Site Number : 7240003
city: Göteborg
country: Sweden
facility: Investigational Site Number : 7520002
city: Luleå
country: Sweden
facility: Investigational Site Number : 7520001
city: Adana
country: Turkey
facility: Investigational Site Number : 7920004
city: Istanbul
country: Turkey
facility: Investigational Site Number : 7920003
city: Izmir
country: Turkey
facility: Investigational Site Number : 7920002
city: Birmingham
country: United Kingdom
facility: Investigational Site Number : 8260002
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: